Comparison of the effects of the three major tyrosine kinase inhibitors as first-line therapy for non-small-cell lung cancer harboring epidermal growth factor receptor mutations

Kinase Inhibitors ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Cost-effectiveness analysis of tyrosine kinase inhibitors (erlotinib, gefitinib, afatinib and osimertinib) as first-line therapy for epidermal growth factor receptor-mutated advanced non-small cell lung cancer

Journal of Chinese Pharmaceutical Sciences ◽

10.5246/jcps.2021.03.021 ◽

2021 ◽

Vol 30 (3) ◽

pp. 253-263

Keyword(s):

Lung Cancer ◽

Kinase Inhibitors ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

First Line Therapy ◽

Effectiveness Analysis ◽

Line Therapy ◽

Management of patients with epidermal growth factor receptor mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC) after radiological progression to first-line therapy with gefitinib.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.e19124 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. e19124-e19124

Author(s):

Yukio Hosomi ◽

Chiharu Tanai ◽

Kiyotaka Yoh ◽

Yasushi Goto ◽

Yasuo Ohashi ◽

...

Keyword(s):

Lung Cancer ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Radiological Progression ◽

First Line Therapy ◽

Line Therapy ◽

Gefitinib with pemetrexed as first-line therapy in patients with advanced nonsquamous non-small cell lung cancer with activating epidermal growth factor receptor mutations

Annals of Translational Medicine ◽

10.21037/atm.2016.12.64 ◽

2017 ◽

Vol 5 (1) ◽

pp. 11-11

Author(s):

Shinkyo Yoon ◽

Dae Ho Lee ◽

Sang-We Kim

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations

British Journal of Cancer ◽

10.1038/sj.bjc.6603393 ◽

2006 ◽

Vol 95 (8) ◽

pp. 998-1004 ◽

Cited By ~ 216

Author(s):

H Asahina ◽

◽

K Yamazaki ◽

I Kinoshita ◽

N Sukoh ◽

...

Keyword(s):

Lung Cancer ◽

Phase Ii Trial ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Pharmacoeconomic Aspects of Different Inhibitors of Tyrosine Kinase in First-Line Therapy of Patients with Advanced Non-Small Cell Lung Cancer with A Mutation in Epidermal Growth Factor Receptor (EGFR) Gene

Value in Health ◽

10.1016/j.jval.2016.09.2139 ◽

2016 ◽

Vol 19 (7) ◽

pp. A720

Author(s):

VV Ryazhenov ◽

SG Gorokhova ◽

V Gorokhov

Keyword(s):

Lung Cancer ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Egfr Gene ◽

First Line Therapy ◽

Line Therapy ◽

Use of Epidermal Growth Factor Receptor Mutation Analysis in Patients with Advanced Non-Small-Cell Lung Cancer to Determine Erlotinib Use as First-Line Therapy

PLoS Currents ◽

10.1371/currents.rrn1245 ◽

2011 ◽

Vol 3 ◽

pp. RRN1245 ◽

Cited By ~ 2

Author(s):

Naoko Ishibe ◽

Josh Carlson ◽

Scott David Ramsey ◽

Andrew Freedman ◽

Sheri Schully

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Thoracic stereotactic body radiation therapy plus first-line tyrosine kinase inhibitors for patients with epidermal growth factor receptor-mutant polymetastatic non-small-cell lung cancer

Medicine ◽

10.1097/md.0000000000027279 ◽

2021 ◽

Vol 100 (37) ◽

pp. e27279

Author(s):

Xia Wang ◽

Zhiqin Lu ◽

Zhimin Zeng ◽

Jing Cai ◽

Peng Xu ◽

...

Keyword(s):

Lung Cancer ◽

Kinase Inhibitors ◽

Stereotactic Body Radiation Therapy ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

Receptor Mutant

Clearing of circulating tumour DNA predicts clinical response to first line tyrosine kinase inhibitors in advanced epidermal growth factor receptor mutated non-small cell lung cancer

Lung Cancer ◽

10.1016/j.lungcan.2019.12.016 ◽

2020 ◽

Vol 141 ◽

pp. 37-43 ◽

Cited By ~ 1

Author(s):

Eva Boysen Fynboe Ebert ◽

Tine McCulloch ◽

Karin Holmskov Hansen ◽

Hanne Linnet ◽

Boe Sorensen ◽

...

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Kinase Inhibitors ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

Circulating Tumour Dna

A review of pharmacological costs of tyrosine kinase inhibitors in first-line for advanced non-small cell lung cancer with activating epidermal growth factor receptor mutations

Annals of Oncology ◽

10.1093/annonc/mdw332.16 ◽

2016 ◽

Vol 27 ◽

pp. iv8

Author(s):

J. Giuliani ◽

A. Bonetti

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Kinase Inhibitors ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

9019 POSTER DISCUSSION Safety Analysis of Patient Subgroups Defined by Low and High Tumour Epidermal Growth Factor Receptor (EGFR) Expression in FLEX Study Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Receiving Chemotherapy With or Without Cetuximab as First-Line Therapy

European Journal of Cancer ◽

10.1016/s0959-8049(11)72331-0 ◽

2011 ◽

Vol 47 ◽

pp. S598

Author(s):

J. von Pawel ◽

R. Pirker ◽

J.R. Pereira ◽

M. Krzakowski ◽

K. Park ◽

...

Keyword(s):

Lung Cancer ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Egfr Expression ◽

Epidermal Growth ◽

Patient Subgroups